News

Ranaz has issued three million units at $0.60 per unit. Each unit comprises one share and half a warrant, with each whole warrant entitling its holder to purchase

The founder and the current CEO, Mohan Uttarwar will remain with the company, serve on the board of directors, and take on the role of chief strategy officer.

Three Rivers Pharmaceuticals will obtain commercial rights to Infergen in all markets except Japan. In addition, Three Rivers Pharmaceuticals will obtain commercial rights to China, effective March 31,

The trial has demonstrated a favorable safety profile with Vivecon in 55 subjects enrolled across nine cohorts. The Phase I trial was designed as a single ascending dose

The supplemental new drug application (sNDA) filing was based upon data from the pivotal registrational trial, which provided estimates of the probability of patients attaining blood pressure goals

The placement was anchored by a commitment of A$6.5 million by existing major shareholders Alta Partners, GBS Venture Partners and Merck Sante, a subsidiary of Merck KGaA. These

The novel devices to be developed by DSM Biomedical and Caliber Therapeutics will enable the controlled and sustained release of drugs to treat vascular diseases such as atherosclerosis.

As part of Genstruct’s executive management team, Mr Latino will lead the company’s global sales efforts, focusing on building the company’s sales infrastructure to drive future growth. In

Under the terms of the agreement, Valeant will purchase all of the outstanding shares of Coria from its parent company, DFB Pharmaceuticals, and other shareholders for $95 million,